Wednesday, February 10, 2010, 4:46pm SGT - The Singapore stock market closes in 14 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Genomic Health Inc. (GHDX)

At 5:00AM SGT: 17.18 USD   0.00 (0.00%)  
 MORE ON GHDX 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Genomic Health, Inc. (NGM:GHDX) Delayed quote dataEdit
Last Trade:17.18 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:17.18
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:21.75
Day's Range:N/A - N/A
52wk Range:15.81 - 27.22
Volume:0
Avg Vol (3m):171,692
Market Cap:491.97M
P/E (ttm):N/A
EPS (ttm):-0.40
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add GHDX to Portfolio   Download Data

 HEADLINES 
•New Star Analyst Rankings for Genomic Health, Inc.
StarMine (Thu, Feb 4)
•GENOMIC HEALTH INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
EDGAR Online (Thu, Feb 4)
•Genomic Health Announces Year-End 2009 Financial Results
PR Newswire (Thu, Feb 4)
•Q4 2009 Genomic Health, Inc. Earnings Release - After Market Close
CCBN (Wed, Feb 3)
•Genomic Health to Announce Fourth Quarter and Year-End 2009 Financial Results and Host Conference Call on Wednesday, February 3
PR Newswire (Wed, Jan 27)
•5 Diagnostics Stocks Get 2010 Buy Rating From Natixis Bleichroeder Expert Industry Analyst
Wall Street Transcript (Mon, Jan 25)
•Gene discovery may help guide breast cancer care
at Reuters (Mon, Jan 25)
•Good News from Genomic Health
Zacks.com (Sat, Jan 23)
•Genomic Health upgraded by Piper Jaffray
Briefing.com (Fri, Jan 22)
•Genomic Health Announces Worldwide Availability of the Oncotype DX(R) Colon Cancer Test
PR Newswire (Thu, Jan 21)
•Genomic Health Announces Publication of Data Demonstrating that the Oncotype DX(R) Breast Cancer Test Significantly Influences Breast Cancer Treatment Decisions, While Increasing Physician Confidence and Patient Satisfaction
PR Newswire (Tue, Jan 12)
More Headlines for GHDX...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.37
EPS Est (in 2 years) (Dec-10) :0.10
Avg Rec (current)*:2.6
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Genomic Health, Inc. operates as a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices